At CELLTIUM, we are driven to excel in the field of biotechnology by developing groundbreaking, first-in-class curative therapies. Our focus encompasses a range of critical neurological disorders, including Charcot-Marie-Tooth disease (CMT), diabetic peripheral neuropathy (DPN), chemotherapy-induced peripheral neuropathy (CIPN), and amyotrophic lateral sclerosis (ALS). Our mission is to transform treatment paradigms in these areas, setting new benchmarks in biotechnological healthcare solutions.